- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00080197
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
10 de octubre de 2006 actualizado por: Eisai Inc.
An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine
The purpose of this study is to determine if E7070 is an efficacious, safe, and tolerable treatment for patients with metastatic breast cancer who have failed, or could not tolerate, prior treatments with an anthracycline, a taxane, and capecitabine.
Descripción general del estudio
Tipo de estudio
Intervencionista
Inscripción
250
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Alberta
-
Edmonton, Alberta, Canadá
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos
-
Hoover, Alabama, Estados Unidos
-
-
Arizona
-
Sedona, Arizona, Estados Unidos
-
-
Colorado
-
Denver, Colorado, Estados Unidos
-
-
Connecticut
-
Torrington, Connecticut, Estados Unidos
-
-
Florida
-
Fort Myers, Florida, Estados Unidos
-
Ocoee, Florida, Estados Unidos
-
Tampa, Florida, Estados Unidos
-
-
Illinois
-
Chicago, Illinois, Estados Unidos
-
Skokie, Illinois, Estados Unidos
-
Urbana, Illinois, Estados Unidos
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos
-
-
Kansas
-
Overland Park, Kansas, Estados Unidos
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos
-
-
Missouri
-
St. Louis, Missouri, Estados Unidos
-
-
New York
-
Albany, New York, Estados Unidos
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos
-
-
Ohio
-
Kettering, Ohio, Estados Unidos
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos
-
Tulsa, Oklahoma, Estados Unidos
-
-
Pennsylvania
-
Clairton, Pennsylvania, Estados Unidos
-
Pittsburgh, Pennsylvania, Estados Unidos
-
Wexford, Pennsylvania, Estados Unidos
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos
-
-
Texas
-
Austin, Texas, Estados Unidos
-
Dallas, Texas, Estados Unidos
-
Fort Worth, Texas, Estados Unidos
-
Fredericksburg, Texas, Estados Unidos
-
Houston, Texas, Estados Unidos
-
Irving, Texas, Estados Unidos
-
Tyler, Texas, Estados Unidos
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos
-
-
Washington
-
Spokane, Washington, Estados Unidos
-
Vancouver, Washington, Estados Unidos
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Patients must be female,
- Patients must have histologically or cytologically confirmed metastatic breast cancer,
- Patients must either have tumors that are resistant/refractory to chemotherapy with an anthracycline, a taxane, capecitabine, and appropriate Herceptin therapy, or tumors that cannot be treated with these agents due to patient's treatment toxicity; therefore, patients must have received 2 prior chemotherapies but no more than 3 prior chemotherapies in the metastatic setting,
- Patients must have at least one uni-dimensionally measurable lesion according to the RECIST criteria in at least one site that has not been irradiated,
- Patients must be aged >= 18 years,
- Patients must have a Karnofsky Performance Status of >= 70%,
- Patients must have a life expectancy of >= 3 months,
- Patients must have adequate renal function as evidenced by serum creatinine <= 1.5 mg/dL, or if > 1.5 but <= 1.8 mg/dL, then a creatinine clearance of >= 45 mL/min,
- Patients must have adequate bone marrow function as evidenced by absolute neutrophil count of >= 1.5 x 109/L, hemoglobin >= 9.0 g/dL, and platelet count >= 100 x 109/L,
- Patients must have adequate liver function as evidenced by bilirubin of <= 1.5 times the upper limits of normal (ULN); alkaline phosphatase <= 3 times ULN and alanine transaminase (ALT) and aspartate transaminase (AST) <= 3 times ULN, unless related to liver metastasis, in which case <= 5 x ULN,
- Patients must have serum electrolytes including calcium (corrected for albumin), magnesium, and potassium (corrected) within normal limits,
- Patients must be willing and able to complete the FACT-B questionnaire,
- Patients must be willing and able to comply with the study protocol for the duration of the study, and
- Patients must give written informed consent prior to any study specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
Exclusion Criteria:
- Patients must not have metastatic disease that can be completely surgically resected,
- Patients who received adjuvant taxane must not have experienced disease progression within 12 months of beginning that therapy,
- Patients must not have received chemotherapy, hormonal therapy, or Herceptin within 2 weeks of E7070 treatment start and must have recovered from any chemotherapy-related or other therapy-related toxicity at study entry,
- Patients must not have received investigational drugs including immunotherapy, gene therapy, or other biologic therapy; antineoplastic therapy; or radiation therapy (other than required for palliation of bone pain or chest ulceration) within 2 weeks of E7070 treatment,
- Patients must not have received prior treatment with Mitomycin C or nitrosoureas,
- Patients must not have undergone high dose chemotherapy with hematopoietic stem cell rescue,
- Patients must not have untreated brain metastases (Patients who have been treated for central nervous system (CNS) metastases must be asymptomatic and radiologically stable [not receiving radiation] and must not have been receiving steroids for 4 weeks prior to entry.
Patients without known CNS metastases who are symptomatic for CNS metastasis must be evaluated with a CT scan or MRI scan prior to E7070 treatment.),
- Patients must not have had major surgery without full recovery within 4 weeks of E7070 treatment start,
- Patients must not have pulmonary lymphatic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen,
- Patients must not have leptomeningeal metastasis,
- Patients must not have evidence of clinically relevant ascites or pleural effusion requiring more than one isolated paracentesis or pleurocentesis per month prior to study start,
- Patients must not be expected to require more than one isolated paracentesis or pleurocentesis per month during the study for the treatment of clinically relevant ascites or pleural effusion,
- Patients must not be pregnant or breast-feeding and must practice adequate contraception if not surgically sterile,
- Patients must not have severe medically uncontrolled intercurrent illness/infection,
- Patients must not have had unstable angina or myocardial infarction in the past 6 months,
- Patients must not have serious cardiac arrhythmia or symptomatic congestive heart failure >= Grade II (NYHA classification),
- Patients must not have a history of prolonged QT, QTc > 470 ms (Bazett's correction) at entry, or history of torsade de pointes,
- Patients must not have recent history (<= 12 months) of active or chronic viral hepatitis,
- Patients must not have organ allografts,
- Patients must not have known history of HIV positivity,
- Patients must not have a history of hypersensitivity to sulfonamides,
- Patients must not have a history of uncontrolled seizures,
- Patients must not have had a prior malignancy, other than carcinoma in situ of the cervix or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence, or
- Patients must not have other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Tasa de respuesta objetiva
|
Medidas de resultado secundarias
Medida de resultado |
---|
La seguridad
|
Calidad de vida
|
Tolerabilidad
|
Sobrevivencia promedio
|
Duración de la respuesta
|
Tiempo hasta la progresión
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Sandra Silberman, M.D., Eisai Inc.
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de febrero de 2004
Finalización del estudio
1 de mayo de 2005
Fechas de registro del estudio
Enviado por primera vez
24 de marzo de 2004
Primero enviado que cumplió con los criterios de control de calidad
24 de marzo de 2004
Publicado por primera vez (Estimar)
25 de marzo de 2004
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
11 de octubre de 2006
Última actualización enviada que cumplió con los criterios de control de calidad
10 de octubre de 2006
Última verificación
1 de octubre de 2006
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- E7070-A001-211
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Neoplasias de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
Ensayos clínicos sobre E7070
-
Eisai Inc.Terminado
-
Eisai Inc.TerminadoNeoplasias Renales | Carcinoma De Célula Renal | Adenocarcinoma De Célula RenalEstados Unidos, Francia
-
Eisai LimitedTerminadoCáncer colorrectal (CCR)Países Bajos, Francia, Alemania
-
Eisai LimitedTerminadoCáncer de mama metastásicoFederación Rusa, Reino Unido, Alemania, Italia, España
-
Eisai Co., Ltd.Terminado
-
Eisai LimitedTerminado
-
M.D. Anderson Cancer CenterEisai Inc.TerminadoLeucemiaEstados Unidos